Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma

Abstract Background Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited. Methods In this study, human osteosarcoma cell lines were...

Full description

Bibliographic Details
Main Authors: Yitian Wang, Wei Yu, Jian Zhu, Junjie Wang, Kaishun Xia, Chengzhen Liang, Huimin Tao
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
CAR-T
CD166
4-1BB
Osteosarcoma
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s13046-019-1147-6

Internet

http://link.springer.com/article/10.1186/s13046-019-1147-6

Similar Items